MAPT and Parkinson disease: The PPMI NeuroEXPLORER study is currently applying high-resolution PET with [18F]PI-2620 to quantify tau pathology in sporadic and LRRK2 PD, aiming to clarify its role in disease heterogeneity and its potential as a biomarker for clinical trials [241].